newsfilter
← Latest News
GlobeNewswire·

DICE Therapeutics Reports First Quarter 2022 Financial Results and Recent Highlights

Topline proof-of-concept data from Phase 1 clinical trial of oral IL-17 antagonist DC-806 in healthy volunteers and psoriasis patients expected in mid-2022 Current cash provides runway through mid-2024 and multiple expected key clinical milestones